SCHEMBL3375688

SCHEMBL3375688

CS(=O)(=O)Nc1ccc(-c2cccc(C(F)(F)F)c2)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.56
NPY5R Q15761 1/20 0.53
EPHX2 P34913 3/20 0.48
NR1H4 Q96RI1 3/20 0.48
CDK1 P06493 2/20 0.48
CCNB1 P14635 2/20 0.48
CCNA2 P20248 2/20 0.48
CDK2 P24941 2/20 0.48
CDK7 P50613 2/20 0.48
CCNH P51946 2/20 0.48
CCNA1 P78396 2/20 0.48
CCND1 P24385 1/20 0.48
CDK6 Q00534 1/20 0.48
RORC P51449 1/20 0.44
RORB Q92753 1/20 0.44
MAPK1 P28482 2/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
BRD4 O60885 1/20 0.44
FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3375693 0.88 KIF11 (0.54) KIF11NPY5REPHX2NR1H4MAPK1
SCHEMBL3375898 0.86 KIF11 (0.58) KIF11NPY5RCDK1CCNB1CCNA2
SCHEMBL3375971 0.85 KIF11 (0.66) KIF11EPHX2NR1H4MAPK1GAA
SCHEMBL4661074 0.83 KIF11 (0.66) KIF11EPHX2NR1H4SCN9A
SCHEMBL3378891 0.83 SLC22A12 (0.52) KIF11MAPK1GAAHPGDBRD4
SCHEMBL3379995 0.82 PGR (0.51) KIF11RORCMAPK1GAAHPGD
SCHEMBL3377794 0.81 DHODH (0.56) KIF11EPHX2NR1H4RORC
SCHEMBL3374813 0.81 KIF11 (0.74) KIF11NPY5RHSD17B2PLAUPLAT
SCHEMBL3377569 0.81 KIF11 (0.51) KIF11EPHX2NR1H4MAPK1GAA
SCHEMBL3377398 0.80 EPHX2 (0.51) KIF11EPHX2NR1H4MAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIF11 3561/4885NPY5R 746/4885EPHX2 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.